COVID-19: Nafamostat inhalation formulation developed: Daiichi Sankyo, RIKEN, Nichiiko, The Univ of Tokyo
COVID-19:
June 8, 2020
The University of Tokyo / RIKEN / Nichi Iko / Daiichi Sankyo
University of Tokyo:
A basic agreement has been reached towards joint research and development of nafamostat inhalation preparations aimed at COVID-19 treatment.
The Univ of Tokyo: Institute of Medical Science
Professor Inoue found that “nafamostat is a drug that blocks the infection and fusion of the outer membrane and cell membrane of COVID-19 virus.”
Nafamostat:
It has been prescribed in Japan for many years as a treatment for acute pancreatitis and disseminated intravascular coagulation.
It is an injectable drug with sufficient clinical data on safety.
RIKEN:
We have established the “Drug Discovery/Medical Technology Platform Program” to promote bridging to companies/medical institutions.
We support research and development using RIKEN’s versatile advanced technology.
Nichiiko:
Manufactured and sold intravenous drip of Fusan® (generic name: nafamostat mesylate) for many years.
We will provide accumulated clinical data and supply the drug substance to this joint research and development.
Daiichi Sankyo:
Utilizing the technology of the anti-influenza virus drug “inavir®”, we will promote research and development of nafamostat/inhalation formulation.
Non-clinical trials will start in July 2020.
We aim to shift to clinical trials by March 2021.
News Release-Daiichi Sankyo